touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)‘ (LBA17) was presented at the Virtual 2020 ESMO Congress, 12–21 September 2020.
- Why is triple-negative breast cancer so hard to treat, and what is the current standard of care for patients with metastatic disease? (0:15)
- Could you tell us a little about sacituzumab govitecan-hziy and its mechanism of action? (1:15)
- What were the aims and design of the ASCENT study? (2:48)
- What were the major efficacy and safety findings of the study? (3:29)
- How will these findings impact on clinical practice and what future studies are planned? (5:07)
Speaker Disclosures: Dr Aditya Bardia declares the following. Consultant/advisor for Biotheranostics, Daiichi Pharma/AstraZeneca, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Puma Biotechnology, Merck, Philipps, Radius Health, Sanofi, Spectrum Pharmaceuticals, Foundation Medicine, and Taiho Pharmaceutical; research funding (to institution) from Biothernostics, Genentech/F. Hoffman-La Roche, Immunomedics, Innocrin Pharmaceuticals, Merck, Mersana Therapeutics, Novartis, Pfizer, Radius Health, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. The ASCENT trial was sponsored by Immunomedics Inc.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!